Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Impedimed's gross profit for the
six
months ended in Dec. 2025 was A$6.58 Mil. Impedimed's gross profit for the trailing twelve months (TTM) ended in Dec. 2025 was A$12.29 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Impedimed's gross profit for the
six
months ended in Dec. 2025 was A$6.58 Mil. Impedimed's Revenue for the
six
months ended in Dec. 2025 was A$7.52 Mil. Therefore, Impedimed's Gross Margin % for the quarter that ended in Dec. 2025 was 87.49%.
Impedimed had a gross margin of 87.49% for the quarter that ended in Dec. 2025 => Durable competitive advantage
During the past 13 years, the highestGross Margin % of Impedimed was 86.93%. The lowest was 66.73%. And the median was 77.50%.
Impedimed (ASX:IPD) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Impedimed had a gross margin of 87.49% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Impedimed Gross Profit Related Terms
Impedimed Gross Profit Historical Data
* Premium members only.
The historical data trend for Impedimed's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Impedimed's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Impedimed Gross Profit vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Impedimed's Gross Profit distribution charts can be found below:
* The bar in red indicates where Impedimed's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$12.29 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Impedimed (ASX:IPD) has a Gross Profit of A$12.29 Mil as of Dec. 2025. Gross Profit equals net sales less total cost of goods sold. View historical data on Impedimed and its competitors.
Is Impedimed's Gross Profit too high?
Impedimed's current Gross Profit is A$12.29 Mil.
How does Impedimed's Gross Profit compare to ABT and SYK?
Impedimed's Gross Profit of A$12.29 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Medical Devices & Instruments company?
A good Gross Profit depends on the Medical Devices & Instruments industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on Impedimed and its competitors. Impedimed's current Gross Profit is A$12.29 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Impedimed stock overvalued right now?
Based on GuruFocus' analysis, Impedimed (ASX:IPD) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.09, compared to a current price of A$0.01 — trading 93.9% below its estimated fair value. The current Gross Profit is A$12.29 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For Impedimed (ASX:IPD), the current Gross Profit is A$12.29 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Impedimed Ltd, together with its subsidiaries, operates in the medical devices space. The company is based in Australia and operates globally, and it generates the majority of its revenue in North America. It is engaged in developing, manufacturing, and distributing noninvasive medical devices. The company offers products that are typically used to assess and monitor lymphedema and heart failure, as well as to measure the tissue composition and fluid status of the patients. The company also offers a cloud-based digital platform (branded as SOZO) to manage patient data. The company recognises revenue from the stand-alone sale of Legacy Devices and Consumables, the Sale of SOZO Devices, and Software Subscription Services.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IPD has been successfully added to your 
